News

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...
Pluvicto is a targeted radioligand therapy, meaning it uses radioactive atoms to deliver radiation to targeted cells, fighting cancer while limiting damage to the surrounding tissues.
The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...
Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key correlates of poor response to therapy.
Swiss pharma giant Novartis AG NVS reported better-than-expected results for the second quarter of 2025 and upped annual ...
Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.
Novartis AG (NVS) reports robust sales and income growth, announces a $10 billion share buyback, and navigates competitive ...
After just one Pluvicto treatment earlier this year, bloodwork showed Coy's cancer level plummeted. Not everyone responds that well to Pluvicto, and things could always change for Coy.
EAST HANOVER, N.J., March 23, 2022 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly ...
The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...